BioSpace News Archive

Pictured: X-ray illustration with the adrenal glan

Neurocrine’s Congenital Adrenal Hyperplasia Candidate Clears Phase III

Topline data for the company’s CRF1 antagonist crinecerfont showed a significant drop in daily glucocorticoid dose, while maintaining androgen control in adult patients with the genetic disorder.

September 13, 2023

·

2 min read

·

Tristan Manalac

Update: AbbVie headquarters building in California

Drug Development

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

September 13, 2023

·

2 min read

·

Tristan Manalac

Pictured: Illustration of liver surrounded by hepa

Drug Development

Eiger Discontinues Phase III Hepatitis Study Due to Safety Concerns

Following cases of hepatobiliary toxicity leading to liver decompensation, Eiger has decided to drop its Phase III LIMT-2 trial of peginterferon lambda in chronic hepatitis delta.

September 13, 2023

·

2 min read

·

Tristan Manalac

Pictured: Facade of Moderna's building in Massachusetts

Drug Development

Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan

The company plans to launch up to 15 new products and bring up to 50 new candidates to the clinic over the next five years as part of its growth plan, while scaling down COVID-19 manufacturing.

September 13, 2023

·

3 min read

·

Kate Goodwin

Drug Development

Alnylam Wins Adcomm’s Support for Heart Disease Drug Despite FDA Concerns

The Cardiovascular and Renal Drugs Advisory Committee voted 9-3 in favor of Alnylam’s patisiran on whether its benefits outweigh its risks for patients with cardiomyopathy induced by transthyretin amyloidosis.

September 13, 2023

·

3 min read

·

Hayley Shasteen

Two scientists collaborating in a laboratory_iStoc

Postdoc Programs at Pharmaceutical Companies: A Research Path Less Chosen

Postdoctoral programs in industry are often overlooked by PhD candidates but they provide certain benefits over academic positions, including better pay.

September 13, 2023

·

4 min read

·

Sanjukta Mondal

Business

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics reported financial results for the first half of 2023 and provided a corporate update.

September 13, 2023

·

8 min read

BioForest

NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

NanoString Technologies, a leading provider of life science tools for discovery and translational research, announced the launch of the latest assay for the GeoMx® Digital Spatial Profiler.

September 13, 2023

·

4 min read

Biotech Beach

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, announced the completion of its business combination with First Light Acquisition Group, a special purpose acquisition company.

September 13, 2023

·

11 min read

Genetown

Arch Therapeutics Provides AC5® Commercialization UpdateOrders and Paid Claims Increasing Since Rollout of Reimbursement Code

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5 ® Advanced Wound System.

September 13, 2023

·

4 min read